[How I treat myelodysplastic symdromes]
- PMID: 28468085
- PMCID: PMC7342718
- DOI: 10.3760/cma.j.issn.0253-2727.2017.04.002
[How I treat myelodysplastic symdromes]
Similar articles
-
NPM1 mutations in myelodysplastic syndromes and acute myeloid leukemia with normal karyotype.Leuk Res. 2007 Jan;31(1):109-11. doi: 10.1016/j.leukres.2006.03.013. Epub 2006 May 5. Leuk Res. 2007. PMID: 16678898
-
Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial.Lancet Haematol. 2020 Apr;7(4):e309-e319. doi: 10.1016/S2352-3026(19)30284-4. Epub 2020 Mar 5. Lancet Haematol. 2020. PMID: 32145771 Clinical Trial.
-
Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study.Lancet Oncol. 2017 Oct;18(10):1338-1347. doi: 10.1016/S1470-2045(17)30615-0. Epub 2017 Sep 1. Lancet Oncol. 2017. PMID: 28870615 Clinical Trial.
-
Differentiation induction therapy of myelodysplastic syndromes.Leuk Res. 1989;13(7):633-7. doi: 10.1016/0145-2126(89)90133-1. Leuk Res. 1989. PMID: 2668648 Review.
-
Darbepoetin alfa for anemia with myelodysplastic syndrome.Expert Rev Hematol. 2015 Apr;8(2):139-46. doi: 10.1586/17474086.2015.1000854. Epub 2015 Jan 12. Expert Rev Hematol. 2015. PMID: 25579702 Review.
References
-
- Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes[J] Blood. 1997;89(6):2079–2088. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical